Trial Profile
S-1 and CPT-11 plus ramucirumab (IRIS+Rmab) as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: A multicenter phase II study in Japan (N-DOCC-F-C-1701)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 May 2019
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Irinotecan (Primary) ; Ramucirumab (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms N-DOCC-F-C-1701
- 29 Apr 2019 According to UMIN, the date for data entry closure is 2019/06/30, and the date for conclusion of data analysis is 2019/12/31.
- 29 Apr 2019 Status changed from recruiting to completed.
- 21 Jul 2017 New trial record